Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Microglia contribute to loss of neurons linked with Alzheimer's disease

Microglia contribute to loss of neurons linked with Alzheimer's disease

Chao BRAIN Center receives $5M gift for study of progressive neurodegenerative diseases

Chao BRAIN Center receives $5M gift for study of progressive neurodegenerative diseases

Pressure BioSciences announces presentations on advantages of PCT

Pressure BioSciences announces presentations on advantages of PCT

Penn Medicine, AstraZeneca collaborate to generate new AD drug candidates

Penn Medicine, AstraZeneca collaborate to generate new AD drug candidates

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

Research shows phenomenon of brain replay is much more complex

Research shows phenomenon of brain replay is much more complex

Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development

Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development

Research confirms benefits of PET scan in early detection of Alzheimer's disease

Research confirms benefits of PET scan in early detection of Alzheimer's disease

Pathway Genomics' personal Genetic Health Report now available

Pathway Genomics' personal Genetic Health Report now available

Methamphetamine abuse during pregnancy leads to structural abnormalities in brain of children

Methamphetamine abuse during pregnancy leads to structural abnormalities in brain of children

Test tube studies offer new hope for Alzheimer’s patients

Test tube studies offer new hope for Alzheimer’s patients

Human amniotic fluid skin cells "reprogrammed" to pluripotency

Human amniotic fluid skin cells "reprogrammed" to pluripotency

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Aging and Alzheimer's disease: Novel brain imaging technologies help create new insights

Aging and Alzheimer's disease: Novel brain imaging technologies help create new insights

This Brain Awareness Week, Canadians are urged to take control and protect their health

This Brain Awareness Week, Canadians are urged to take control and protect their health

Researchers discover microtentacles that play key role in spreading cancer to distant locations in body

Researchers discover microtentacles that play key role in spreading cancer to distant locations in body

UC Irvine researchers play leading role in genome sequencing of Hydra

UC Irvine researchers play leading role in genome sequencing of Hydra

New study finds green tea extract may prevent Alzheimer's disease and dementia

New study finds green tea extract may prevent Alzheimer's disease and dementia

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Eisai, Johns Hopkins University's BSI enter into licensing agreement for GCPII technology

Eisai, Johns Hopkins University's BSI enter into licensing agreement for GCPII technology

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.